Cargando…

Incretin-Based Therapy and Risk of Pancreatic Cancer in Patients with Type 2 Diabetes Mellitus: A Meta-analysis of Randomized Controlled Trials

INTRODUCTION: The present study aims to evaluate the risk of pancreatic cancer with incretin-based therapy among patients with type 2 diabetes mellitus (T2DM). METHODS: We searched EMBASE, MEDLINE, the Cochrane Central Register of Controlled Trials and ClinicalTrials.gov for eligible studies publish...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Han, Zhou, Xiaoying, Chen, Tao, Liu, Bingtuan, Jin, Wujuan, Gu, Huiyuan, Hong, Tianyuan, Zhang, Guoxin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5118236/
https://www.ncbi.nlm.nih.gov/pubmed/27655330
http://dx.doi.org/10.1007/s13300-016-0198-3
_version_ 1782468912547364864
author Chen, Han
Zhou, Xiaoying
Chen, Tao
Liu, Bingtuan
Jin, Wujuan
Gu, Huiyuan
Hong, Tianyuan
Zhang, Guoxin
author_facet Chen, Han
Zhou, Xiaoying
Chen, Tao
Liu, Bingtuan
Jin, Wujuan
Gu, Huiyuan
Hong, Tianyuan
Zhang, Guoxin
author_sort Chen, Han
collection PubMed
description INTRODUCTION: The present study aims to evaluate the risk of pancreatic cancer with incretin-based therapy among patients with type 2 diabetes mellitus (T2DM). METHODS: We searched EMBASE, MEDLINE, the Cochrane Central Register of Controlled Trials and ClinicalTrials.gov for eligible studies published up to March 06 2016. This meta-analysis includes all studies reporting adverse events of pancreatic cancer with use of incretin-based therapies compared with placebo or non-incretin anti-diabetic drugs in patients with T2DM. We used fixed-effect model to compare pooled relative risk (RR) with related 95% confidence intervals (CI). RESULTS: A total of 159 randomized trials were identified. Out of these, 135 studies were excluded as pancreatic cancer occurrence had not been included as an end point. The remaining 24 trials enrolling 47,904 participants were further assessed. Overall, no increased risk of pancreatic cancer were detected in association with incretin-based treatment (RR = 0.7, 95% CI 0.37–1.05). The incidence of pancreatic neoplasm was even lower among incretin-based groups than controls (RR = 0.50, 95% CI 0.29–0.87) in trials with duration more than 104 weeks. There was even decreased risk of pancreatic cancer within groups paralleled by incretin-matched placebos (RR = 0.55, 95% CI 0.32–0.93) than by non-incretin anti-diabetic drugs. Neither monotherapy (RR = 0.62, 95% CI 0.38–1.01) nor combination regimen (RR = 0.92, 95% CI 0.45–1.90) of incretin mimetics increased the risk of pancreatic cancer. CONCLUSION: This meta-analysis shows that incretin-based therapies are not associated with increase in the risk of pancreatic cancer. Interestingly, subgroup analyses suggested lower risk of pancreatic cancer in incretin groups than placebo in long-term studies (>104 weeks). Considering the inconsistent results among randomized trials and previous epidemiological investigations, more such studies should be conducted to clarify the existence or non-existence of this association. FUNDING: This work was supported by grants from the National Natural Science Foundation of China (Nos. 81270476 and 81470830). ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s13300-016-0198-3) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5118236
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Springer Healthcare
record_format MEDLINE/PubMed
spelling pubmed-51182362016-12-05 Incretin-Based Therapy and Risk of Pancreatic Cancer in Patients with Type 2 Diabetes Mellitus: A Meta-analysis of Randomized Controlled Trials Chen, Han Zhou, Xiaoying Chen, Tao Liu, Bingtuan Jin, Wujuan Gu, Huiyuan Hong, Tianyuan Zhang, Guoxin Diabetes Ther Original Research INTRODUCTION: The present study aims to evaluate the risk of pancreatic cancer with incretin-based therapy among patients with type 2 diabetes mellitus (T2DM). METHODS: We searched EMBASE, MEDLINE, the Cochrane Central Register of Controlled Trials and ClinicalTrials.gov for eligible studies published up to March 06 2016. This meta-analysis includes all studies reporting adverse events of pancreatic cancer with use of incretin-based therapies compared with placebo or non-incretin anti-diabetic drugs in patients with T2DM. We used fixed-effect model to compare pooled relative risk (RR) with related 95% confidence intervals (CI). RESULTS: A total of 159 randomized trials were identified. Out of these, 135 studies were excluded as pancreatic cancer occurrence had not been included as an end point. The remaining 24 trials enrolling 47,904 participants were further assessed. Overall, no increased risk of pancreatic cancer were detected in association with incretin-based treatment (RR = 0.7, 95% CI 0.37–1.05). The incidence of pancreatic neoplasm was even lower among incretin-based groups than controls (RR = 0.50, 95% CI 0.29–0.87) in trials with duration more than 104 weeks. There was even decreased risk of pancreatic cancer within groups paralleled by incretin-matched placebos (RR = 0.55, 95% CI 0.32–0.93) than by non-incretin anti-diabetic drugs. Neither monotherapy (RR = 0.62, 95% CI 0.38–1.01) nor combination regimen (RR = 0.92, 95% CI 0.45–1.90) of incretin mimetics increased the risk of pancreatic cancer. CONCLUSION: This meta-analysis shows that incretin-based therapies are not associated with increase in the risk of pancreatic cancer. Interestingly, subgroup analyses suggested lower risk of pancreatic cancer in incretin groups than placebo in long-term studies (>104 weeks). Considering the inconsistent results among randomized trials and previous epidemiological investigations, more such studies should be conducted to clarify the existence or non-existence of this association. FUNDING: This work was supported by grants from the National Natural Science Foundation of China (Nos. 81270476 and 81470830). ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s13300-016-0198-3) contains supplementary material, which is available to authorized users. Springer Healthcare 2016-09-21 2016-12 /pmc/articles/PMC5118236/ /pubmed/27655330 http://dx.doi.org/10.1007/s13300-016-0198-3 Text en © The Author(s) 2016 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Original Research
Chen, Han
Zhou, Xiaoying
Chen, Tao
Liu, Bingtuan
Jin, Wujuan
Gu, Huiyuan
Hong, Tianyuan
Zhang, Guoxin
Incretin-Based Therapy and Risk of Pancreatic Cancer in Patients with Type 2 Diabetes Mellitus: A Meta-analysis of Randomized Controlled Trials
title Incretin-Based Therapy and Risk of Pancreatic Cancer in Patients with Type 2 Diabetes Mellitus: A Meta-analysis of Randomized Controlled Trials
title_full Incretin-Based Therapy and Risk of Pancreatic Cancer in Patients with Type 2 Diabetes Mellitus: A Meta-analysis of Randomized Controlled Trials
title_fullStr Incretin-Based Therapy and Risk of Pancreatic Cancer in Patients with Type 2 Diabetes Mellitus: A Meta-analysis of Randomized Controlled Trials
title_full_unstemmed Incretin-Based Therapy and Risk of Pancreatic Cancer in Patients with Type 2 Diabetes Mellitus: A Meta-analysis of Randomized Controlled Trials
title_short Incretin-Based Therapy and Risk of Pancreatic Cancer in Patients with Type 2 Diabetes Mellitus: A Meta-analysis of Randomized Controlled Trials
title_sort incretin-based therapy and risk of pancreatic cancer in patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled trials
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5118236/
https://www.ncbi.nlm.nih.gov/pubmed/27655330
http://dx.doi.org/10.1007/s13300-016-0198-3
work_keys_str_mv AT chenhan incretinbasedtherapyandriskofpancreaticcancerinpatientswithtype2diabetesmellitusametaanalysisofrandomizedcontrolledtrials
AT zhouxiaoying incretinbasedtherapyandriskofpancreaticcancerinpatientswithtype2diabetesmellitusametaanalysisofrandomizedcontrolledtrials
AT chentao incretinbasedtherapyandriskofpancreaticcancerinpatientswithtype2diabetesmellitusametaanalysisofrandomizedcontrolledtrials
AT liubingtuan incretinbasedtherapyandriskofpancreaticcancerinpatientswithtype2diabetesmellitusametaanalysisofrandomizedcontrolledtrials
AT jinwujuan incretinbasedtherapyandriskofpancreaticcancerinpatientswithtype2diabetesmellitusametaanalysisofrandomizedcontrolledtrials
AT guhuiyuan incretinbasedtherapyandriskofpancreaticcancerinpatientswithtype2diabetesmellitusametaanalysisofrandomizedcontrolledtrials
AT hongtianyuan incretinbasedtherapyandriskofpancreaticcancerinpatientswithtype2diabetesmellitusametaanalysisofrandomizedcontrolledtrials
AT zhangguoxin incretinbasedtherapyandriskofpancreaticcancerinpatientswithtype2diabetesmellitusametaanalysisofrandomizedcontrolledtrials